EP1398032A1 — 4-Oxo-quinazolines as LXR nuclear receptor binding compounds
Assigned to Phenex Pharmaceuticals AG · Expires 2004-03-17 · 22y expired
What this patent protects
The present invention relates to 4-oxo-quinazolines which bind to the Liver X receptors (LXR receptors, LXRalpha/NR1 H3 and LXRbeta/NR1H2) and act as selective agonists of the LXR receptors. The invention further relates to the treatment of diseases and/or conditions through bind…
USPTO Abstract
The present invention relates to 4-oxo-quinazolines which bind to the Liver X receptors (LXR receptors, LXRalpha/NR1 H3 and LXRbeta/NR1H2) and act as selective agonists of the LXR receptors. The invention further relates to the treatment of diseases and/or conditions through binding of said nuclear receptors and selective agonistic effects by said compounds and the production of medicaments using said compounds. In particular the compounds are useful in the treatment of hypercholesterimia, obesity or other diseases associated with elevated lipoprotein (LDL) levels.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.